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Objectives. This study in patients with diabetes mellitus was 
undertaken 1) to evaluate cardiac sympathetic innervation in 
diabetic patients using metaiodobenzylguanidine (MIBG) imag- 
ing; 2) to study the relation between autonomic function assessed 
by clinical maneuvers and abnormalities in MIBG uptake; and 
3) to examine the basis for our previous observation of an 
association between abnormalities in autonomic nervous system 
dysfunction and silent myocardial ischemia. 
Background. The clinical detection of autonomic dysfunction in 
diabetes mellitus has been linked to both abnormal perception of 
pain, including angina, and poor prognosis. 
Methods. Uptake of MIBG was measured by dual-isotope 
imaging in 23 normal subjects and 65 asymptomatic diabetic 
patients. Silent myocardial ischemia was defined as the presence 
of a reversible perfusion defect in patients with ST segment 
depression. 
Results. The MIBG uptake in the diabetic patients was signif- 
icantly lower than that in normal subjects in the apex (67 _+ 17% 
vs. 82 _+ 7%, p = 0.0001), distal third (77 -+ 11% vs. 85 -+ 3%, p = 
0.0001), proximal third (77 -+ 9% vs. 84 -+ 3%, p = 0.0001) and 
base (71 + 9% vs. 80 -+ 4%, p = 0.0001) of the left ventricle. 
Similarly, MIBG uptake was variable across different vascular 
territories. When MIBG uptake was corrected for perfusion 
abnormalities, diabetic patients had a greater MIBG uptake 
defect than normal subjects on visual score assessment (16 +- 13 
vs. 8 -+ 7%, p = 0.0002) and on quantitative MIBG mismatch 
assessment (13 -+ 15% vs. 2 -+ 2%, p = 0.0001). Diabetic patients 
with versus without autonomic dysfunction had more extensive 
MIBG uptake mismatch (17 -+ 17% vs. 4 + 6%, p = 0.0001). There 
was a greater diffuse abnormality in diabetic patients with versus 
without silent myocardial ischemia detected by sestamibi/MIBG 
uptake ratio (68 +- 35% vs. 19 -+ 33%, p = 0.001). 
Conclusions. Sympathetic ardiac innervation in normal sub- 
jects is inhomogeneous. In contrast to normal subjects, diabetic 
patients have evidence of a significant reduction in MIBG uptake, 
most likely on the basis of autonomic dysfunction. Furthermore, 
diabetic patients with silent myocardial ischemia have evidence of 
a diffuse abnormality in MIBG uptake, suggesting that abnormal- 
ities in pain perception may be linked to sympathetic denervation. 
(J Am CoU Cardiol 1995;25:610-8) 
Cardiac autonomic dysfunction has traditionally been assessed 
indirectly by standardized bedside maneuvers (1). This assess- 
ment has been most relevant in patients with diabetes mellitus, 
in whom detection of autonomic dysfunction has been linked 
to both poor overall prognosis (2,3) and sudden cardiorespi- 
ratory death (4-8). The presence of diabetic autonomic neu- 
ropathy has also been related to silent myocardial infarction 
(9). More recently, we demonstrated an association between 
autonomic dysfunction and silent myocardial ischemia (10), 
suggesting that autonomic dysfunction i volving afferent sym- 
pathetic trunks, which form part of the cardiac pain perception 
pathway, may be linked to the lack of symptoms in diabetic 
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patients. Because diabetic patients are at a greater isk for 
development of coronary artery disease (11), this attenuated 
perception of myocardial ischemia and infarction is of partic- 
ular relevance in diabetic patients. 
A more direct, noninvasive and quantitative assessment of
cardiac autonomic dysfunction is possible with iodine-123 
(I-123) metaiodobenzylguanidine (MIBG), a norepinephrine 
analog that shares the same uptake-I mechanism into sympa- 
thetic nerve terminals (12,13). Abnormalities in myocardial 
MIBG uptake have been related to sympathetic denervation i
the setting of left ventricular damage or dysfunction associated 
with cardiomyopathy (14-17), myocardial infarction (18-21) 
and long QT syndrome (22) and, anecdotally, in patients with 
generalized autonomic neuropathy (23). However, to our 
knowledge, systematic assessment of cardiac sympathetic 
denervation has not been performed in patients with diabetes 
mellitus. Accordingly, this study was undertaken 1) to evaluate 
cardiac sympathetic innervation in diabetic patients by means 
of MIBG imaging with the hypothesis that a greater MIBG 
abnormality will be detected among those with clinical evi- 
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dence of autonomic dysfunction; and 2) to examine the basis of 
our previous observation of an association between diabetic 
autonomic dysfunction and silent myocardial ischemia. 
Methods  
Patients. Patients with type 2 diabetes mellitus according 
to the criteria of National Diabetes Group (24) who were >35 
years old were recruited from the diabetic clinic at St. Mi- 
chael's Hospital and Sunnybrook Medical Centre from July 
1989 to December 1991. All patients completing the protocol 
were included. All diabetic patients had no cardiac symptoms 
(e.g., angina) and had a normal cardiovascular physical exam- 
ination and 12-lead electrocardiogram (ECG) at rest. Nondi- 
abetic subjects of similar age were used as control subjects. The 
protocol and consent form were approved by the Human 
Subjects Review Committee of the University of Toronto and 
the Institutional Review Boards of the participating hospitals. 
All subjects who were approached provided written informed 
consent. 
All diabetic patients underwent autonomic function tests 
and MIBG imaging for assessment of cardiac sympathetic 
denervation. All diabetic patients also underwent ambulatory 
ECG monitoring and exercise testing for detection of ST 
segment depression. Those patients with ST segment depres- 
sion underwent repeat stress testing with sestamibi imaging for 
further validation of the presence of inducible myocardial 
ischemia. 
Medications capable of interfering with assessment of au- 
tonomic function, MIBG imaging or exercise testing (e.g., 
beta-adrenergic blocking agents or calcium antagonists or 
sympatholytic drugs) were withheld at least 48 h before these 
tests. 
Autonomic function tests. The following five simple, repro- 
ducible bedside maneuvers previously reported (25,26) were 
performed to assess autonomic function. 1) Valsalva maneuver 
(40 mm Hg for 15 s); end point is the ratio of the longest o the 
shortest RR interval (normal ->1.21). 2) Deep breathing (6 
breaths/min); end point is mean difference between maximal 
and minimal heart rate (normal -16 beats/min). 3) Response to 
standing (ratio of the longest o the shortest RR interval); end 
point is the so-called 30:15 ratio (normal ->1.04). 4) Blood 
pressure response to standing (difference in systolic blood pres- 
sure; normal is 10 mm Hg). 5) Sustained hand grip (30% of the 
maximal voluntary contraction); end point is the difference in 
diastolic blood pressure (normal ->16 mm Hg). 
On the basis of previous studies (25,26), autonomic dys- 
function was defined as an abnormal response to two or more 
of the five tests, which has been shown to occur in <1.6% of 
nondiabetic patients. To assess the specificity of these auto- 
nomic function tests, they were performed in 20 nondiabetic 
control patients with stable angina and angiographically doc- 
umented coronary artery disease (->50% stenosis in at least 
one vessel); only 1 (5%) of 20 patients had two abnormal 
responses. 
Ambulatory ECG monitoring. A two-channel (leads V 5 
and aVF), 48-h amplitude-modulated monitor was used (Mar- 
quette Electronics) for detection of ambulatory ST segment 
depression. Particular care was taken to prepare lectrode sites 
with skin abrasion techniques. The ST segment responses to 
postural changes and hyperventilation were evaluated to rule 
out spurious ST segment depression or elevation. Patients 
exhibiting those responses were excluded from further testing. 
A significant episode of ST segment depression was defined 
as -0.1 mV of horizontal or downsloping ST segment depres- 
sion occurring 60 to 80 ms after the J point, lasting -1 rain and 
separated from other episodes by -> 1 min. 
Exercise testing. Exercise testing was performed according 
to the Bruce protocol (27) in the postabsorptive state between 
9:00 AM and 1:00 PM. Heart rate was monitored continuously, 
and a 12-lead ECG was obtained every 30 s for purposes of ST 
segment analysis. Exercise was discontinued if target heart rate 
was achieved, if fatigue preventing further exercise developed 
or if systolic blood pressure decreased ->10 mm Hg from 
baseline. 
Significant ST segment depression on exercise testing was 
defined as ->0.1 mV of horizontal or downsloping ST segment 
depression measured 60 to 80 ms after the J point and present 
on at least one lead. 
Exercise sestamibi imaging. For the purpose of this study, 
silent myocardial ischemia was defined as a reversible defect 
on visual and quantitative s stamibi scintigraphy in patients 
with documented ST segment depression on either exercise 
testing or ambulatory ECG monitoring. We previously re- 
ported a sensitivity of 90% and a specificity of 80% for 
detection of coronary stenosis ->50% using this quantitative 
analysis (28). 
The rest sestamibi imaging was performed first as part of 
the MIBG dual-imaging protocol (see later), at which time 
8 mCi of technetium-99m (Tc-99m) sestamibi was injected, and 
imaging commenced 1 h later. 
After dual imaging was completed, the exercise portion of 
the sestamibi study was performed only in patients with 
previously documented ST segment depression on ambulatory 
ECG monitoring or exercise testing ->6 h after the rest 
injection on the same or the following day. At peak exercise, 
20 mCi of Tc-99m sestamibi was injected intravenously, and 
exercise continued for a further 60 s. Tomographic images 
were obtained 30 rain after injection, and a total 180 °circular 
orbit continuous acquisition was performed in 20 min in 3 ° 
increments. 
Images were interpreted by an independent experienced 
observer unaware of the results of autonomic function tests, 
exercise testing or ambulatory ECG monitoring. Visual im- 
pression of a reversible defect had to be corroborated by 
quantitative analysis. Defect size was expressed as a percent of 
the total bull's-eye for each vascular territory and the total, 
according to the methods developed and validated in our 
laboratory (28). 
MIBG imaging. In the fasting state, all patients had 5 to 
8 mCi of 1-123 MIBG injected intravenously for assessment of
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sympathetic denervation. Five hours after the injection, 8mCi 
of Tc-99m sestamibi was injected intravenously. One hour 
later, dual tomographic imaging was performed using an 
Elscint tomographic system with a general all-purpose collima- 
tor. Five milliliters of 1% Lugol's solution was given 72 h 
before and 48 h after the administration f MIBG. 
Imaging was performed in the prone position to eliminate 
diaphragmatic attenuation and to limit liver uptake affecting 
the MIBG image, with 180 o continuous circular acquisition 
starting in the 45 ° right anterior oblique position for 20 min. 
Sixty images were acquired with images tored in 3 o increments 
in a 64 × 64 matrix. Short-axis, vertical long-axis and horizon- 
tal long-axis lices, each 1 pixel thick, were generated. 
Visual interpretation. Two experienced physicians without 
knowledge of clinical status or autonomic function testing 
interpreted the images divided into 13 segments (one apical 
segment in addition to proximal, mid and distal segments in 
anterior, septal, inferior and posterolateral territories). Uptake 
in each segment was scored from 0 = normal to 4 = no uptake, 
and the maximal abnormal score was 52. To account for 
abnormal MIBG uptake on the basis of perfusion abnormali- 
ties, a corrected MIBG defect score was generated by subtract- 
ing the sestamibi score from the M1BG score on a segment- 
by-segment basis and then averaged for all 13 segments. 
Quantitative analysis'. The details of data processing and 
assessment of cross talk between sestamibi and MIBG are 
described in the Appendix. 
To study whether MIBG uptake was homogeneous, we 
compared uptake not only in anterior, septal, posterolateral, 
inferior and apical segments, but also along the long axis of the 
left ventricle to four levels: apex, distal third, middle third and 
base (Fig. 1). At each level, the iodine-123 activity as a percent 
of maximum was determined from the bull's-eye. 
A mismatch of MIBG was determined by localizing all 
MIBG uptake defects and comparing these with the sestamibi 
quantification. If a sestamibi defect was present in the same 
distribution, this was considered concordant, and the MIBG 
defect was attributed to reduction of perfusion rather than 
sympathetic dysfunction. Similarly, abnormal MIBG uptake 
compared with normal sestamibi uptake was considered indic- 
ative of an abnormality in sympathetic nnervation and was 
identified as MIBG mismatch. 
Heart/lung ratios of MIBG were calculated from an ante- 
rior planar image that was acquired for 5 rain in a 128 x 128 
matrix before tomographic a quisition. In the diabetic subjects, 
heart/lung ratios were calculated only in anterior or inferior 
segments that were not associated with an M1BG defect 
identified by quantitative analysis. 
To improve detection of diffuse abnormalities in MIBG 
uptake, a sestamibi/MIBG ratio utilizing a midventricular 
short-axis slice was calculated. Circumferential profiles of 
sestamibi and MIBG uptake were generated, and the sestamibi 
curve was divided by the MIBG curve to generate the ratio of 
activity. The normal ratio of the 360 ° circumference was 
generated with the lower limits of this ratio calculated as the 
mean value minus two standard deviations in the normal 
subjects. An abnormality was expressed as a percent of the 
total circumferential profile below two standard eviations of 
the lower limit of normal and localized to each of three 
vascular territories. 
Validation. We evaluated quantitative MIBG scintigraphy 
in mongrel dogs with (n = 4) and without (n = 4) pacing- 
induced congestive heart failure. There was a significant 
correlation (r = 0.71, p = 0.01) between heart/lung ratio of 
MIBG uptake and left ventricular norepinephrine content 
(29). 
Echocardiography. To study the possible impact of auto- 
nomic dysfunction and silent myocardial ischemia on left 
ventricular systolic and diastolic function, two-dimensional 
echocardiography was performed in diabetic patients. 
Systolic function was measured using percent fractional 
shortening, which was based on the measurement of left 
ventricular cavity at end-diastole minus the end-systolic mea- 
surement divided by the end-diastolic measurement; all mea- 
surements were made in parasternal short-axis view at the tips 
of the papillary muscle. Diastolic function was assessed using 
Doppler measurement of mitral valve inflow pattern and 
expressed as the early diastolic/atrial filling (E/A) ratio. 
Left ventricular hypertrophy may affect both the specificity 
of ambulatory ST segment depression for detection of myo- 
cardial ischemia nd diastolic function. Therefore, we mea- 
sured left ventricular posterior wall and intraventricular septal 
thickness and defined left ventricular hypertrophy as-> 1.2 cm. 
Data analysis. All data are expressed as mean value _+ SD. 
Subjects were grouped according to the presence of autonomic 
dysfunction and silent myocardial ischemia. Group compari- 
sons were performed using an unpaired t test for continuous 
variables and chi-square analysis for discrete data. The MIBG 
uptake at various levels along the left ventricular long axis and 
between segments in different vascular territories was com- 
pared using analysis of variance with repeated measures and 
the Yukey test. The impact of silent myocardial ischemia on 
M1BG uptake was studied using analysis of covariance. To 
study the possible interaction between silent myocardial isch- 
emia and MIBG uptake across different regions of the left 
ventricle (score), repeated measures two-way analysis of vari- 
ance was utilized. 
Resu l ts  
Autonomic function and MIBG scintigraphy. Sixty-five di- 
abetic patients underwent MIBG scintigraphy. Clinical assess- 
ment of autonomic function in these patients revealed abnor- 
mal responses to none of the five standard bedside maneuvers 
in 11% of subjects, to one maneuver in 18%, to two maneuvers 
in 40%, to three maneuvers in 16%, to four maneuvers in 9% 
and to five maneuvers in 6% of subjects. Thus, autonomic 
dysfunction, defined as abnormal responses to at least two 
maneuvers, was present in 71% of subjects. Comparison of 
patients with and without autonomic dysfunction is shown in 
Table 1 and revealed a greater prevalence ofhypertension a d 
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Table I. Clinical Characteristics of 88 Study Patients 
Autonomic Dysfunction Silent Myocardial lsehemia 
No Yes No Yes 
(n= 19) (n 46) (n=44)  (n -21)  
Age (yr) 52 _+ 13 56 + III 53 -+ 11 60 ± 9* 
Gender (M/Y) 15/4 35/11 31/13 19/2 
Family history 63% 73% 73% 63% 
Smoking 13% 17% 12% 25% 
Hypertension 6% 46%* 37% 31% 
Obesity 25 % 39% 37% 31% 
Diabetes duration (yr) 12 + 9 13 _+ 10 12 + 10 13 + 9 
Insulin therapy 58% 5[1% 50% 57% 
Hb A~,. 8.2 + 2.{)% 8.1 +_ 2.7% 8.3 + 2.8% 7.8 + 1.3% 
FBS (~tg/ml) 8 -+ 4 10 + 4 9 ± 4 8 -+ 4 
Total cholesterol (mg/dl) 186 _+ 46 209 + 43 205 + 46 201 -+ 46 
Triglycerides (mg/dl) 133 -+ 106 230 _+ 1597 204 ± 159 186 + 106 
LDL (mg]dl) 104 _+ 23 124 + 275 112 ± 27 135 + 27~: 
HDL (mg/dl) 47 + 15 44 _+ 9 46 + 12 43 + 12 
Fibrinogen (mg/dl) 240 -+ 60 260 -+ 80 240 -+ 70 310 -+ 70t 
*p = 0.005. )p - 0.03. :I:p - 0,01. Data prcsentcd are mean value + SD or number or percent of patients. F - female; 
FBS fasting blood sugar; HDL (LDL) = high (low) density lipoprotein cholesterol; Hb Ale = hemoglobin Ale; M - 
male. 
higher serum triglyceride and low density lipoprotein (LDL) 
cholesterol levels among patients with autonomic dysfunction 
(46% vs. 6%, p = 0.005). 
Comparison of exercise testing variables in patients with 
and without autonomic dysfunction is demonstrated in Table 2. 
Patients with autonomic dysfunction had a higher rest systolic 
blood pressure and rate-pressure product and exercised for a 
shorter time. The duration of the exercise tests and the 
maximal rate pressure product achieved attest to the good 
exercise tolerance of these patients who were completely free 
from cardiovascular symptoms. 
The MIBG uptake was nonhomogeneous in normal control 
subjects and diabetic patients (Fig. 1), with the lowest uptake 
in the apex compared with the middle two thirds of the left 
ventricle; MIBG uptake in diabetic patients was significantly 
lower than that in normal subjects at all levels of the left 
ventricular long axis. Nonhomogeneous MIBG uptake was also 
found in vascular territories (Fig. 1). In normal subjects, the 
lowest uptake was found in the inferior compared with the 
anterior or posterolateral segments, and septal and apical 
segments had intermediate uptake and did not differ signifi- 
cantly from the other segments. In diabetic patients, more 
obvious spatial differences emerged, with the lowest uptake in 
inferior and apical segments compared with the posterolateral 
segment, which, in turn, had a lower uptake of MIBG than the 
septal and anterior segments. The MIBG uptake was lower in 
diabetic patients than in normal subjects in all segments except 
septal segments (Fig. 1). 
There was a striking difference in the extent of MIBG 
uptake abnormalities in diabetic patients compared with nor- 
mal subjects (Fig. 2). After MIBG uptake was corrected for 
any perfusion abnormalities, the 65 diabetic patients had a 
greater mismatch in MIBG uptake than the 23 normal sub- 
jects, as evidenced by visual MIBG corrected defect score 
(16 _+ 13 vs. 8 -+ 7, p = 0.0002) and MIBG mismatch (13 _+ 
15% vs. 2 _+ 2%, p = 0.0001). The differences in visual MIBG 
corrected defect score between diabetic patients and normal 
subjects were seen across all vascular territories: left anterior 
Table 2. Results of Exercise Testing 
Autonomic Dysfunction Silent Myocardial Ischemia 
No Yes No Yes 
(n = 19) (n - 46) (n = 44) (n - 21) 
Duration (mini 9.9 ± 2.9 7.2 + 2.5* 8.4 _+ 2.8 7 _+ 3 
Rest HR (beats/mini 84 + 9 85 + 16 84 + 14 87 + 15 
Rest systolic BP (ram Hg) 124 _+ 13 140 + 16" 134 -+ 18 140 -+ 13 
Rest RPP 10_+ 2 12 + 2? 11 ± 2 12-+ 2 
Maximal HR (beats/mini 153 _+ 15 150 + 16 153 _+ 15 143 _+ 16t 
Maximal systolic BP (ram Hg) 179 + 17 186 _+ 19 184 + 21 184 + 14 
Maximal RPP 27 = 3 28 + 4 28 _+ 4 26 + 4 
*p = 0.005. tp  = 0.03. Data presented are mean value + SD. RPP - rate-pressure product (Heart rate [HR] x 
Systolic blood pressure [BP] x 103). 
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Figure 1. Uptake of metaiodobenzylguanidine wasassessed at four 
levels along the long axis of the left ventricle as identified in the 
schematic diagram (top left) and in vascular territories (bottom left). 
Comparison between normal subjects and diabetic patients across 
these four levels and vascular territories is summarized by p values 
(rightmost column). *p < 0.05 for comparison between different levels 
and vascular territories within normal subjects and diabetic patients 
when significant. See text for further comparison of dual-imaging 
results in normal subjects and diabetic patients. 
descending coronary artery (6.1 +_ 7.1 vs. 2.1 _+ 2.7, p = 
0.0003), left circumflex coronary artery (4.4 _+ 4.5 vs. 1.9 +_ 2.7, 
p = 0.003) and right coronary artery (5.9 _+ 3.9 vs. 4.1 +_ 2.8, 
p = 0.02). For MIBG mismatch, these differences were, 
respectively, 9.8 _+ 14.9 versus 1.9 _+ 3.3 (p = 0.0001); 17.8 +_ 
Figure 2. Dual imaging with sestamibi and metaiodobenzylguanidine 
(MIBG) in normal subjects and diabetic patients demonstrated normal 
perfusion in both, but a significant decrease in MIBG uptake in 
diabetic patients involving distal anterior, apical and inferior segments. 
SESTAMIBI 
NORMAL DIABETIC 
IDI 
1123 MIBG 
NORMAL DIABETIC 
25.9 versus 2.5 _+ 6.5 (p = 0.0001); and 14.8 _+ 22.7 versus 1.4 _+ 
3.3 (p = 0.0001). 
Among diabetic patients, those with autonomic dysfunction 
had a greater abnormality in MIBG uptake than patients 
without autonomic dysfunction (MIBG corrected efect score 
19 +_ 14 vs. 10 +_ 5, p = 0.0001; MIBG mismatch 17 _+ 17% vs. 
4 + 6%, p = 0.0001). No differences were found between 
patients with and without autonomic dysfunction (33 + 39% 
vs. 41 _+ 46%, p = 0.5) using the sestamibi/MIBG ratio. 
Overall, there were weak correlations between the results of 
clinical assessment of autonomic dysfunction as measured by a 
number of abnormal responses to the battery of five clinical 
tests and the assessment of abnormality in MIBG uptake as 
measured by visual (r = 0.32, p = 0.01) or quantitative MIBG 
mismatch (r = 0.29, p = 0.02); no correlation was found with 
the sestamibi/MIBG ratio (r = 0.13, p = 0.3). 
Similarly, a weak but significant inverse relation was de- 
tected between the size of MIBG mismatch and the measure of 
sympathetic nfluence on heart rate variability expressed as the 
area under the curve of the low frequency band (r = -0.38, 
p = 0.006). 
To further evaluate diffuse abnormalities in MIBG uptake 
and to account for potential confounding effects of serum 
catecholamines, we assessed the heart/lung ratio in diabetic 
patients using only those territories judged normal by visual 
and quantitative assessment. The heart/lung ratio was lower in 
diabetic patients than in normal subjects (1.22 _+ 0.18 vs. 
1.56 + 0.28, p = 0.05). 
Silent myocardial isehemia. Among the 65 diabetic sub- 
jects, 21 had silent myocardial ischemia on the basis of the 
previously reported (10) definition of a reversible defect on 
exercise myocardial perfusion study in conjunction with ST 
segment depression on exercise testing (n = 6) or Holter 
monitoring (n = 2), or both (n = 13). 
Comparison of baseline clinical characteristics between 
patients with and without silent myocardial isehemia is shown 
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Table 3. Results of Echocardiographic Assessment 
Autonomic Silent Myocardial 
Dysfunction Ischemia 
No Yes No Yes 
(n : 16) (n : 40) (n = 39) (n = 17) 
LV size (ram) 
End-systolic 2.7 _+ 0.6 2.7 _+ 0.4 2.8 _+ 0.6 2.6 _+ 0.3 
End-diastolic 4.7 _+ 0.5 4.5 + 0.6 4.6 _+ 0.6 4.5 _+ 0.4 
LV systolic function 42 + 9 40 _+ 8 40 _+ 9 43 + 7 
(% FS) 
LV diastolic function 1.3 -+ 0.5 1.0 _+ 0.4 1.2 + 1).4 1).9 + 0.4* 
(E/A ratio) 
LV thickness (cm) 1.0 _+ 0.l 1.0 + 0.1 1.0 _+ 0.1 1.1) _+ 0.1 
LV hypertrophy 6% 15% 8% 23% 
*p = 0.02. Data presented are mean value = SD, unless otherwise indicatcd. 
E/A ratio = early diastolic/atrial filling ratio; FS - fractional shortening; LV - 
left ventricular. 
in Table 1: patients with silent myocardial ischemia were older 
and had higher serum LDL cholesterol and fibrinogen levels. 
The results of Holter monitoring in patients with silent 
myocardial ischemia revealed 1.4 __ 1.5 episodes/24 h (range 0 
to 5), with a mean duration of 11 _+ 14 rain (range 0 to 55). 
The location of perfusion abnormalities in the 21 patients 
with silent myocardial ischemia was anterior in 29%, posterior 
in 47% and both in 24%. The mean defect size was 7 _+ 8%; it 
was 3 + 4% in anterior and 5 -- 7% in posterior distributions 
(p = 0.2). 
Comparison of the exercise testing variables between pa- 
tients with and without silent myocardial ischemia is shown in 
Table 2: Maximal heart rate achieved was lower in patients 
with silent myocardial ischemia; however, no difference in 
maximal rate-pressure product was detected. 
No differences were found between patients with and 
without silent myocardial ischemia in MIBG corrected efect 
score (17 _+ 12% vs. 16 _+ 14%, p = 0.8); MIBG mismatch 
(13 + 15% vs. 13 _+ 16%, p = 0.9); or heart/lung ratio (1.27 _+ 
0.13 vs. 1.35 + 0.29, p = 0.32). 
When abnormalities in MIBG uptake were studied using 
the quantitative sestamibi/MIBG ratio, patients with silent 
myocardial ischemia were found to have a greater abnormality 
than those without silent myocardial ischemia (68 _+ 35% vs. 
19 _+ 33%, p -- 0.001). 
To study the possible interaction between silent myocardial 
ischemia and MIBG uptake across different regions of left 
ventricle, two-way analysis of variance with repeated measures 
was utilized. There was a trend (p = 0.09) for greater 
sympathetic denervation i patients with than those without 
silent myocardial ischemia as studied across various long-axis 
levels of the left ventricle and between vascular territories as 
depicted in Figure 1. 
Assessment of left ventricular function. Left ventricular 
systolic function and size did not differ in patients with or 
without autonomic dysfunction or silent myocardial ischemia 
(Table 3); no wall motion abnormalities were reported in any 
of these patients. Diastolic dysfunction was greater in patients 
with than without silent myocardial ischemia (Table 3). How- 
ever, when age differences were taken into account by analysis 
of covariance, no significant differences were detected (cor- 
rected E/A ratio 1.0 vs. 1.1, respectively; F = 1.13, p = 0.29). 
There was no difference in left ventricular thickness or 
frequency of hypertrophy between groups (Table 3). However, 
left ventricular wall thickness was greater (1.1 _+ 0.1 cm) in 
diabetic patients with than without a clinical history of hyper- 
tension (0.99 _+ 0.1, p = 0.01). 
Discuss ion  
The principal findings of this study are 1) detection of 
nonhomogeneous MIBG uptake in healthy subjects; 2) greatly 
diminished MIBG uptake in patients with diabetes mellitus, 
especially those with clinically detectable autonomic dysfunc- 
tion; and 3) greater diffuse abnormality in MIBG uptake in 
diabetic patients with silent myocardial ischemia. 
Historically, detection of autonomic dysfunction has been 
based on abnormal responses inheart rate or blood pressure to 
various bedside maneuvers (1). More recently, diminished 
heart rate variability has been demonstrated in relation to 
diabetic autonomic dysfunction (30-32). Both of these ap- 
proaches have significant limitations in that they do not 
directly assess ympathetic cardiac innervation, lack the ability 
to interrogate specific anatomic regions and are nonquantita- 
tire and thereby subject to large measurement variability. 
These limitations are overcome by the objective and quantita- 
tive assessment of myocardial MIBG uptake. 
Assessment of cardiac sympathetic innervation. The use of 
MIBG imaging for assessment of cardiac sympathetic innerva- 
tion has been validated with tissue norepinephrine content 
(29,33), and assessment of sympathetic innervation i animals 
(34-36) has demonstrated a catecholamine gradient with 
higher levels at the cardiac base than at the apex. We also 
found a lower MIBG uptake at the apex compared with the 
middle two-thirds of the left ventricle. The lower uptake at the 
base of the heart may have resulted from tissue attenuation, 
although prone imaging to prevent diaphragmatic attenuation 
was performed. There was nonhomogeneous uptake of MIBG 
across the vascular territories in normal subjects, with the 
inferior wall having the lowest MIBG uptake. Because MIBG 
uptake was corrected for any regional differences in myocar- 
dial perfusion, our findings provide evidence for nonhomoge- 
neous sympathetic innervation across vascular territories and 
along the long axis of the normal eft ventricle. The findings of 
greater sympathetic innervation i  the anterior wall are con- 
gruent with previous clinical observations (36,37) of greater 
sympathetic a tivity (e.g., tachycardia orhypertension) i  acute 
anterior than inferior myocardial infarction. 
Although MIBG uptake in diabetic patients had a similar 
distribution to that in normal subjects with more pronounced 
regional differences, diabetic patients had lower MIBG uptake 
at all levels of the left ventricle and in all vascular territories 
with the exception of the septal segment. Furthermore, we 
found evidence for greater abnormalities in MIBG uptake in 
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diabetic patients with clinically detectable autonomic dysfunc- 
tion. 
Pathophysiology of silent myocardial ischemia. Patients 
with diabetes mellitus provide a unique opportunity to study 
the pathophysiology of silent myocardial ischemia because of a 
higher incidence of coronary artery disease on the one hand 
and a predisposition toabnormal pain perception on the other. 
Previous autopsy findings (9) suggested a link between silent 
myocardial infarction and diabetic neuropathy. Using clinical 
assessment of autonomic dysfunction, we have also demon- 
strated its relation to silent myocardial ischemia in asymptom- 
atic diabetics (10). The present report confirms and extends 
those observations; patients with silent myocardial ischemia 
have a greater abnormality in sestamibi/MIBG ratio, indicative 
of a generalized cardiac sympathetic denervation. Thus, the 
lack of symptoms in these patients in association with myocar- 
dial ischemia may have resulted from diffuse denervation on 
the basis of diabetic autonomic dysfunction involving afferent 
sympathetic trunks, which form the most distal part of the pain 
perception pathway from cardiac pain receptors to the spi- 
nothalamic tract, thalamus and cortex. A limitation of these 
observations relates to the inability of MIBG imaging to 
distinguish between afferent and efferent sympathetic nerve 
endings. However, it is likely that diabetic neuropathy--a 
systemically generalized process--would affect both limbs of 
the sympathetic system similarly. Lack of a significant differ- 
ence between patients with and without silent myocardial 
ischemia using MIBG mismatch was most likely related to the 
finding that this particular methodology is sensitive to regional 
differences but may not detect a diffuse and homogeneous 
decrease in MIBG uptake. 
It should be appreciated that patient enrollment in this 
study was not consecutive, and, therefore, the proportion of 
patients with silent myocardial ischemia undergoing MIBG 
imaging cannot be used to approximate the overall prevalence 
of silent myocardial ischemia in asymptomatic diabetic pa- 
tients. This was found to be 17% in our previous report (10). 
Assessment of silent myocardial ischemia was based on a 
reversible myocardial perfusion defect in patients with ST 
segment depression on either exercise testing or ambulatory 
ECG monitoring. Because of the 90% sensitivity and 80% 
specificity of this approach (28), it is conceivable that up to 
four patients with silent myocardial isehemia in our study may 
not have had angiographic evidence of significant atheroscle- 
rosis. This would not be surprising in that the pathophysiology 
of myocardial ischemia in diabetic subjects may be related to 
small vessel disease (38,39), abnormal myocardial capillaries 
(40-42), abnormal vasoreactivity (43), endothelial dysfunction 
(44,45), increased platelet aggregability (46-48), decreased red 
cell deformability (48) and hyperfibrinogenemia (47,49,50). 
Previous studies dealing with abnormalities in MIBG up- 
take have dealt with patients with abnormal eft ventricular 
function related to either myocardial infarction (19-21) or 
cardiomyopathy (14-17). Thus, previous observations of sym- 
pathetic denervation have been in a setting of myocardial 
damage, which presumably resulted in injury to contiguous 
sympathetic nerve trunks. Our findings of cardiac sympathetic 
denervation during systematic assessment of patients without 
left ventricular systolic or diastolic dysfunction suggest hat 
sympathetic denervation may occur in the absence of signifi- 
cant left ventricular dysfunction. Hence, we believe that these 
data provide the first evidence supporting neuropathic sympa- 
thetic denervation rather than denervation on the basis of 
direct damage from necrosis, such as seen in acute myocardial 
infarction. 
Conclusions. The future direction of cardiac MIBG imag- 
ing in diabetic and other patients hould include assessment of
the potential for reversibility of sympathetic denervation in 
relation to, for example, enhanced control of diabetes mellitus. 
Because the development of autonomic dysfunction i diabetic 
patients is associated with an extremely poor prognosis (2-8) 
and may be a harbinger of lethal arrhythmias in patients with 
coronary artery disease, early detection and the ability to 
monitor its extent should lead to a more focused therapeutic 
approach in the management of these patients. 
We acknowledge the research assistance of Heather Hink, RN; the expert 
technical support of Lois Adams, BSc, Terry Hsia, RT, BSc, the Eehoeardio- 
graphic Laboratory and Dr. R. J. Howard; and the secretarial ssistance of Gail 
Karaim and Linda Gray. 
Appendix 
Data Processing 
For each normal subject and diabetic patient, a three-dimensional 
polar plot or bull's-eye was generated (51) for both sestamibi and 
metaiodobenzylguanidine (MIBG). Short-axis slices, each 1 pixel thick, 
were sampled from the endocardial surface of the apex to five slices 
from the base of the myocardium. For each slice a circumferential 
profile was generated from the myocardial maximal pixel count value 
along 60 radial rays at 6 ° intervals. The circumferential data of the first 
slice was utilized to generate the sixth ring of the bull's-eye plot. The 
subsequent slices were represented in each subsequent ring. The 
thickness of each ring varied depending on the number of short-axis 
slices utilized to generate the bull's-eye. Each patient's bull's-eye was 
of constant dimensions. 
The vertical long-axis lices, also 1 pixel in thickness, were sampled 
from the subendocardial surface of the septum to the lateral wall of the 
myocardium. Each slice was sampled for the maximal pixel count value 
along 10 radial rays at 6 ° intervals from 30 ° inferior of the apex to 30 ° 
anterior of the apex. The results are mapped as vertical columns, with 
the number of columns equal to the number of slices sampled. 
Interpolative smoothing was applied, and the width of each column 
varied according to the number of vertical ong-axis lices utilized. 
These data representing the apex were applied in the area of the five 
central rings of the bull's-eye plot. 
From the 23 normal bull's-eye plots, an average bull's-eye was 
generated to represent the normal distribution of MIBG and sesta- 
mibi. A bull's-eye representing the lower limits of normal, that is, 2.5 
standard eviations below the normal bull's-eye, was generated for 
each of sestamibi and MIBG, and defects were defined and localized to 
a vascular territory. 
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Signal to Noise Assessment 
To limit the cross talk between sestamibi and MIBG in the 
dual-imaging protocol, asymmetric windows of 15% at the 140- and 
159-keV photopeaks were utilized. The windows were placed such that 
10% of the window was utilized in the lower portion of the 140-keV 
peak and 10% in the upper portion of the 159-keV photopeak. To 
study the extent of cross talk we performed MIBG imaging (N = 14) 
at 4 h after iodine-123 (I-123) injection and before technetium-99m 
(Tc-99m) sestamibi njection and 1 h later, after technetium-99m 
injection. There was 2.1 _+ 1.3% (range 0.1% to 4.4%) additional 
counts in the 5-h images compared with the 4-h images, demonstrating 
low cross talk of Tc-99m sestamibi into the 1-123 MIBG images. We 
also assessed the ability to identify correctly the size of a known defect 
by utilizing a cardiac phantom with concentrations of iodine-123 and 
technetium-99m that were present in our studies of men. A standard 
10% defect of iodine-123 or technetium-99m was created, and tomo- 
graphic imaging was performed in normal subjects and in diabetic 
patients. Defect size was determined from the bull's-eye format, as 
discussed in the text. In the presence of a known 10% standard efect 
of iodine-123 with normal technetium-99m uptake, the calculated 
iodine-123 defect was at 11.8%, and there was no technetium-99m 
defect. With a known 10% standard efect in technetium-99m uptake 
and normal iodine-123, the calculated iodine-123 defect was 1%, 
confirming the previous observation of minimal cross talk. When there 
was a known 10% standard efect in both iodine-123 and technetium- 
99m uptake, the calculated efects were 11.2% and 11.1%, respectively. 
Given this information, and because in the quantitative method discussed 
in the text we correct all 1-123 MIBG defects for perfusion abnormalities, 
we believe there would be no significant overestimation of iodine-123 
defect size in the patients. 
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